The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial

Summary

The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be more effective than standard treatment, which is a combination of chemotherapy and radiotherapy.

Timeline

Start

2018-08-30

Primary completion

2022-11-18

Completion

2022-11-18

Outcome

Met primary endpoint

paper The 1-year PFS rate is 76%, satisfying our efficacy objective. PMID 37988638 ↗

Publications

• Results https://www.redjournal.org/article/S0360-3016(24)00859-9/fulltext
• Ohri N, Jolly S, Cooper BT, Kabarriti R, Bodner WR, Klein J, Guha C, Viswanathan S, Shum E, Sabari JK, Cheng H, Gucalp RA, Castellucci E, Qin A, Gadgeel SM, Halmos B. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol. 2024 Feb 10;42(5):562-570. doi: 10.1200/JCO.23.00627. Epub 2023 Nov 21.

Drugs

Indications